Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.
Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.
Chimeric antigen receptor (CAR)-T cell immunotherapy is under intense preclinical and clinical investigation, and it involves a rapidly increasing portfolio of novel target antigens and CAR designs. We established a platform that enables rapid and high-throughput CAR-screening campaigns with reporter cells derived from the T cell lymphoma line Jurkat. Reporter cells were equipped with nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NFAT) reporter genes that generate a duplex output of enhanced CFP (ECFP) and EGFP, respectively. As a proof of concept, we modified reporter cells with CD19-specific and ROR1-specific CARs, and we detected high-level reporter signals that allowed distinguishing functional from non-functional CAR constructs. The reporter data were highly reproducible, and the time required for completing each testing campaign was substantially shorter with reporter cells (6 days) compared to primary CAR-T cells (21 days). We challenged the reporter platform to a large-scale screening campaign on a ROR1-CAR library, and we showed that reporter cells retrieved a functional CAR variant that was present with a frequency of only 6 in 1.05 × 10. The data illustrate the potential to implement this reporter platform into the preclinical development path of novel CAR-T cell products and to inform and accelerate the selection of lead CAR candidates for clinical translation.
嵌合抗原受体 (CAR)-T 细胞免疫疗法正在进行深入的临床前和临床研究,涉及到越来越多的新型靶抗原和 CAR 设计。我们建立了一个平台,该平台使用源自 T 细胞淋巴瘤系 Jurkat 的报告细胞,能够快速且高通量地进行 CAR 筛选实验。报告细胞配备了核因子 κB (NF-κB) 和活化 T 细胞核因子 (NFAT) 报告基因,分别产生增强型 CFP (ECFP) 和 EGFP 的双输出。作为概念验证,我们用 CD19 特异性和 ROR1 特异性 CAR 对报告细胞进行了修饰,并检测到高水平的报告信号,允许区分功能性和非功能性 CAR 构建体。报告数据高度可重现,与使用原代 CAR-T 细胞 (21 天) 相比,使用报告细胞完成每次测试实验的时间大大缩短 (6 天)。我们在 ROR1-CAR 文库中对报告平台进行了大规模筛选实验,并表明报告细胞检索到了一个功能型 CAR 变体,其频率仅为 1.05×10 的 6 次方。这些数据说明了将该报告平台应用于新型 CAR-T 细胞产品的临床前开发路径的潜力,并为临床转化的 CAR 候选物的选择提供信息和加速。